ASH 2020 | CITADEL-203: parsaclisib in R/R follicular lymphoma
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses CITADEL-203 (NCT03126019), a mulitcenter Phase II trial aiming to evaluate the efficacy and safety of parsaclisib in relapsed/refractory (R/R) follicular lymphoma (FL) patients. Following parsaclisib treatment, patients presented a very high objective response rate (ORR). Most patients experienced only mild treatment-emergent adverse events (TEAEs), however non-fatal TEAEs leading to dose interruption or dose reduction also occurred. These findings show that parsaclisib therapy leads to high rates of rapid and durable responses, indicating it has potential as a novel treatment in R/R FL patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Ryan Lynch, MD, has received research funding from TG Therapeutics, Takeda, Incyte, Rhizen Pharmaceuticals, Bayer, Cyteir, and Genentech, and has done consultancy for MorphoSys.
